button bars forest bayes pooled summary circles
 
DCR

malignant mesothelioma (mMS) - 1st line (L1) malignant mesothelioma (mMS) - 1st line (L1)

versus pemetrexed plus platin
nivolumab plus ipilimumab vs. pemetrexed plus platin 1 certainty unassessable-39%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons